GLS and cancer: CB-839 inhibits cancer cell proliferation by blocking GLS1 activity in TNBC cells and interfering with glutamine utilization, glutamate synthesis, oxygen consumption, and glutathione levels, as well as intermediates in the tricarboxylic acid cycle (Gross et al., 2014).